Clinical data in relation to PCR results (tyrosinase or MelanA/MART1)
| Variable . | PCR positive (n = 11) . | PCR negative (n = 99) . | P* . | |||
|---|---|---|---|---|---|---|
| Age | ||||||
| Median (y) | 64 | 61 | 0.4 | |||
| Range | 36-85 | 16-93 | ||||
| Karnofsky performance status | ||||||
| ≥90% | 10 (91%) | 93 (94%) | 0.5 | |||
| <90% | 1 (9%) | 6 (6%) | ||||
| Sex | ||||||
| Female | 5 (45%) | 47 (47%) | 1 | |||
| Male | 6 (55%) | 52 (53%) | ||||
| Largest tumor diameter | ||||||
| ≤14 mm | 4 (36%) | 39 (39%) | 1 | |||
| >14 mm | 6 (55%) | 56 (57%) | ||||
| Ciliary body involvement | ||||||
| No | 7 (64%) | 63 (64%) | 1 | |||
| Yes | 4 (36%) | 36 (36%) | ||||
| Extraocular growth | ||||||
| No | 9 (82%) | 91 (92%) | 0.3 | |||
| Yes | 2 (18%) | 8 (8%) | ||||
| Variable . | PCR positive (n = 11) . | PCR negative (n = 99) . | P* . | |||
|---|---|---|---|---|---|---|
| Age | ||||||
| Median (y) | 64 | 61 | 0.4 | |||
| Range | 36-85 | 16-93 | ||||
| Karnofsky performance status | ||||||
| ≥90% | 10 (91%) | 93 (94%) | 0.5 | |||
| <90% | 1 (9%) | 6 (6%) | ||||
| Sex | ||||||
| Female | 5 (45%) | 47 (47%) | 1 | |||
| Male | 6 (55%) | 52 (53%) | ||||
| Largest tumor diameter | ||||||
| ≤14 mm | 4 (36%) | 39 (39%) | 1 | |||
| >14 mm | 6 (55%) | 56 (57%) | ||||
| Ciliary body involvement | ||||||
| No | 7 (64%) | 63 (64%) | 1 | |||
| Yes | 4 (36%) | 36 (36%) | ||||
| Extraocular growth | ||||||
| No | 9 (82%) | 91 (92%) | 0.3 | |||
| Yes | 2 (18%) | 8 (8%) | ||||
Fisher's exact test or, in case of age, Mann-Whitney U test.